Provided by Tiger Trade Technology Pte. Ltd.

Roivant Sciences Ltd.

35.00
+0.29000.84%
Volume:205.65K
Turnover:7.17M
Market Cap:25.28B
PE:-74.47
High:35.18
Open:34.65
Low:34.65
Close:34.71
52wk High:37.97
52wk Low:11.94
Shares:722.41M
Float Shares:581.00M
Volume Ratio:3.51
T/O Rate:0.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4700
EPS(LYR):-0.5400
ROE:-8.52%
ROA:-16.48%
PB:5.98
PE(LYR):-64.81

Loading ...

Roivant to Report Q1 Results, Host Conference Call and Webcast

Reuters
·
Jul 24

Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026

THOMSON REUTERS
·
Jul 24

Immunovant Announces Annual Shareholder Meeting

Reuters
·
Jul 23

Arbutus Biopharma, Genevant sue Pfizer, BioNTech Over Lipid Nanoparticle Patents

MT Newswires Live
·
Jul 16

Immunovant CEO Eric Venker Disposes of Common Shares Worth $3.46 Million

Reuters
·
Jul 07

Roivant Director Meghan Fitzgerald Disposes of 10,000 Common Shares Worth $349,000

Reuters
·
Jul 03

Roivant Sciences Director Melissa B. Epperly Disposes of Common Shares Worth $610,588.76

Reuters
·
Jul 02

QVT Financial Reports Roivant Sciences Common Share Disposal Worth $48.57 Million

Reuters
·
Jul 01

Is Roivant Sciences (ROIV) Losing Its Defensive Status or Reframing Its Risk Narrative?

Simply Wall St.
·
Jun 30

Roivant President, CIO Mayukh Sukhatme Disposes of Common Shares Worth $34.1 Million

Reuters
·
Jun 30

Immunovant Director Atul Pande Disposes of 1,500 Common Shares for $57,015

Reuters
·
Jun 27

Roivant Sciences President and Immunovant CEO Eric Venker Disposes of Common Shares Worth $6.63 Million

Reuters
·
Jun 27

Immunovant director Atul Pande disposes of USD 51,030 common shares

Reuters
·
Jun 17

Piper Sandler Sticks to Their Buy Rating for Roivant Sciences (ROIV)

TIPRANKS
·
Jun 16

Immunovant director Andrew J. Fromkin reports common share disposal worth $7.44 million

Reuters
·
May 30

Roivant Sciences Is Maintained at Buy by Guggenheim

Dow Jones
·
May 26

Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Crescent Biopharma (CBIO) and Genmab (GMAB)

TIPRANKS
·
May 26

Roivant Sciences price target raised to $31.50 from $29.50 at BofA

TIPRANKS
·
May 25

Roivant President, Immunovant CEO Eric Venker disposes common shares worth $7.23 million

Reuters
·
May 23

Should Roivant’s One‑Off Driven Profitability Shift Require Action From Roivant Sciences (ROIV) Investors?

Simply Wall St.
·
May 22